News

elve Pitt faculty members have recently been selected to present their research for the 2025 Senior Vice Chancellor’s Research Seminar Series.

This annual lecture series, also known as the 12@12 series, focuses on research by young investigators in the biomedical sciences. Selection criteria include a nomination from a senior faculty member and involvement in a research project that fits into one of four categories: cutting-edge fundamental research

Congratulations to Thomas Karikari, PhD (Assistant Professor of Psychiatry and Endowed Faculty Fellow in Peripheral Biomarkers for Brain Diseases), and Victor Villemagne, MD (Levidow-Pittsburgh Foundation Chair in Alzheimer’s Disease and Dementia Disorders and Professor of Psychiatry), who have been named…

A recent study utilized the NULISA platform to evaluate a broad panel of biomarkers, including amyloid, tau, glial, vascular, and co-pathology markers, in cognitively normal individuals to better understand early Alzheimer’s pathology. Based on the results, this multimodal approach could help redefine how we identify and predict Alzheimer’s in its preclinical stages. Learn more with study co-author Dr. Thomas Karikari, Director of the Biofluid Biomarker Laboratory at the University of Pittsburgh and an Assistant Professor of Psychiatry at the University of Pittsburgh.

The data on Alzheimer’s disease in Black communities is stark: The risk is higher than average, but the rate of diagnosis is delayed.

To address that, several University of Pittsburgh researchers from different departments are partnering with the Allegheny County Health Department and the Black Equity Coalition (BEC) in a new interdisciplinary effort.

The Brain and Cognitive Health Equity Campaign for Allegheny County…

Pittwire | November 20, 2024 |
Gloved hands place viles into a holder
Twenty-four University of Pittsburgh researchers have been named to this year’s Highly Cited Researchers list, an annual compilation of researchers whose work has made a significant impact across a broad range of disciplines. Last year, 23 Pitt researchers were included. The list…

University of Pittsburgh | University of Pittsburgh scientists independently validated a new blood test platform that can simultaneously measure more than a hundred biomarkers of Alzheimer’s disease. The platform might improve clinicians’ ability to capture the multifaceted nature of Alzheimer’s pathology and streamline early…

By Hannah Flynn | Medical News Today There is still research to be done into the best type of biomarkers to detect Alzheimer’s disease in different types of body fluid, said Dr. Thomas K Karikari, assistant professor of psychiatry at the University of Pittsburgh, who...

By Anastasia Gorelova | University of Pittsburgh | PITTSBURGH — Why do some people develop Alzheimer’s disease while others don’t? And, even more puzzlingly, why do many individuals whose brains are chock-full of toxic amyloid aggregates — a telltale sign of Alzheimer’s brain pathology — never go on to develop Alzheimer’s-associated dementias?

By Tom Avril | The Philadelphia Inquirer The FDA may approve a new drug for Alzheimer’s as soon as this week. But policy experts warn that the health care system is ill-equipped to identify which patients might be eligible for the drug, called lecanemab, as the...